# Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease

> **NCT06065605** · — · UNKNOWN · sponsor: **Lysosomal and Rare Disorders Research and Treatment Center, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Fabry Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06065605
- **Lead sponsor:** Lysosomal and Rare Disorders Research and Treatment Center, Inc.
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-14
- **Primary completion:** 2025-07-12
- **Final completion:** 2025-09-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06065605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06065605, "Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06065605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*